Antengene

Antengene

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines.

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene has established a pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets, four early-stage clinical assets. In addition, leveraging R&D capabilities, Antengene are internally developing six pre-clinical stage assets, which focus on novel targets or MoAs and hence have potential to address significant unmet medical needs. More importantly, these assets target the key oncogenic pathways and are highly synergistic to our pipeline assets.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Antengene funding round, January 2019
120,000,000
January 2019
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
November 23, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Eudora Wang
November 20, 2020
DealStreetAsia
Fidelity and GIC, were among the cornerstone investors in the IPO.
Qiming Venture Partners
November 20, 2020
www.prnewswire.com:443
/PRNewswire/ -- Qiming's portfolio company Antengene (SEHK: 6996) officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. The...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.